S
Suzanne Oparil
Researcher at University of Alabama at Birmingham
Publications - 941
Citations - 122414
Suzanne Oparil is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Blood pressure & Angiotensin II. The author has an hindex of 106, co-authored 885 publications receiving 113983 citations. Previous affiliations of Suzanne Oparil include Michigan State University & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.
Elizabeth Ofili,Suzanne Oparil,Thomas D. Giles,Bertram Pitt,Das Purkayastha,Robert Hilkert,Rita Samuel,James R. Sowers +7 more
TL;DR: Amlodipine/valsartan/HCTZ combination therapy was efficacious across racial/ethnic subgroups and Maximal efficacy was obtained with intensive treatment.
Journal ArticleDOI
Proposed Changes for NIH's Center for Scientific Review
Bruce Alberts,Francisco J. Ayala,David Botstein,Ellen Frank,Edward W. Holmes,Ronald Lee,Eduardo R. Macagno,Philippa Marrack,Suzanne Oparil,Stuart H. Orkin,Arthur H. Rubenstein,Carolyn W. Slayman,P. Frederick Sparling,Larry R. Squire,Peter H. von Hippel,Keith R. Yamamoto +15 more
TL;DR: The Panel on Scientific Boundaries for Review as mentioned in this paper examined the organization and function of the review process carried out by the Center for Scientific Review (CSR) at the National Institutes of Health (NIH).
Journal ArticleDOI
An Update on Refractory Hypertension
Faris Matanes,M. Bilal Khan,Mohammed Siddiqui,Tanja Dudenbostel,David A. Calhoun,Suzanne Oparil +5 more
TL;DR: Refractory hypertension (RfHTN) is defined as blood pressure (BP) that is uncontrolled despite using ≥ 5 antihypertensive medications of different classes, including a long-acting thiazide diuretic and a mineralocorticoid receptor antagonist (MRA) at maximal or maximally tolerated doses as discussed by the authors .
Journal ArticleDOI
Preparative isolation of angiotensin-converting enzyme from human lung
Qing Cheng Meng,Steven J. King,Keith E. Branham,Lawrence J. DeLucas,Bernard Lorber,Suzanne Oparil +5 more
TL;DR: Angiotensin-converting enzyme from human lung was purified to apparent homogeneity using a five-step purification procedure consisting of ammonium sulfate precipitation, ion-exchange chromatography on DEAE Sephadex A-50, gel permeation on SepHadex G-200, chromatofocusing on a polybuffer exchange column and high-performance liquid chromatographic gel permeations on a Bio-Sil TSK-250 column.
Journal ArticleDOI
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
George L. Bakris,Lin Zhao,Stuart Kupfer,Attila Juhasz,Michie Hisada,Eric E. Lloyd,Suzanne Oparil +6 more
TL;DR: Both AZL‐M/CLD and OLM/HCTZ showed similar efficacy and tolerability in hypertensive participants with stage 3 chronic kidney disease, and a greater proportion of participants up‐titrated to the highest dose with OLM or HCTZ.